Document is current
Any future updates will be listed below
-
Authors
Schmitz, Matthias https://orcid.org/0000-0002-5502-681X
Canaslan, Sezgi
Espinosa, Juan Carlos
Fernández-Borges, Natalia
Villar-Piqué, Anna
Llorens, Franc
Varges, Daniela
Maass, Fabian
Torres, Juan Maria
Hermann, Peter
Zerr, Inga
-
Funding
Funding for this research was provided by:
Fundació La Marató de TV3 (201821-30)
Alzheimer Forschung Initiative (20026)
Robert Koch-Institute through funds of the Federal Ministry of Health (1369-341)
CJD Foundation (Implementation of a blood-based biomarker test for sporadic Creutzfeldt-Jakob in clinical practice)
- License Information
-
More Information
Article History
Received: 11 February 2022
Accepted: 18 May 2022
First Online: 18 June 2022
Declarations
:
: The study was conformed to the Code of Ethics of the World Medical, approved by the local ethics committee in Göttingen 24/8/12, “Biomarker-based Diagnosis of rapidly progressive dementias – optimization of diagnostic protocols.” Informed consent was obtained from all subjects involved in the study. All animal experiments are carried out following the Spanish guidelines by Directive 2010/63/EU of the European Union and made every effort to minimize suffering. Animal experiments were evaluated by the Committee on the Ethics of Animal Experiments of the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria and approved by the General Directorate of the Madrid Community Government (permit no. PROEX 094/18 and PROEX 291/19).
: Informed consent to participate in the study was obtained from all participants included in the study.
: Informed consent for publication was obtained from all participants included in the study.
: The research involves human and animal samples.
: Informed consent was obtained from all individual participants included in the study.
: The authors declare no competing interests.
